Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry. Implications for drug addiction, sleep and pain

Progress in Neurobiology

Volumn 83, Issue 5, 2007, Pages 332-347

  Ferre S ^a   Diamond, I ^b   Goldberg, S R ^a   Yao, L ^b   Hourani, S M O ^c   Huang, Z L ^d,e   Urade, Y ^d   Kitchen, I ^c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b CV THERAPEUTICS INC   (United States)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d OSAKA BIOSCIENCE INSTITUTE   (Japan)

^e FUDAN UNIVERSITY   (China)

Author keywords

Adenosine A2A receptor; Drug addiction; Hypothalamus; Pain; Peripheral nervous system; Sleep; Striatum

Indexed keywords

2 [(2 AMINOETHYLAMINO)CARBONYLETHYL PHENYLETHYLAMINO] 5' N ETHYLCARBOXAMIDO ADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE; LEVODOPA; MORPHINE; OPIATE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

BRAIN; CORPUS STRIATUM; DRUG DEPENDENCE; DRUG POTENTIATION; HYPOTHALAMUS; NARCOLEPSY; NOCICEPTION; NONHUMAN; NUCLEUS ACCUMBENS; PAIN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SLEEP; SLEEP DISORDER; SLEEP WAKING CYCLE; ADDICTION; ANIMAL; BASAL GANGLION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NERVE TRACT; PATHOPHYSIOLOGY;

ADENOSINE; ANIMALS; BASAL GANGLIA; HUMANS; HYPOTHALAMUS; NEURAL PATHWAYS; PAIN; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; SLEEP DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 36148933708     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2007.04.002     Document Type: Review

References (185)

1. Abo-Salem O.M., Hayallah A.M., Bilkei-Gorzo A., Filipek B., Zimmer A., and Muller C.E. Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 308 (2004) 358-366
2. Agnati L.F., Ferré S., Lluis C., Franco R., and Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55 (2003) 509-550
3. Ahlijanian M.K., and Takemori A.E. Effects of (-)-N6-(-phenylisopropyl)-adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. Eur. J. Pharmacol. 112 (1985) 171-179
4. Aley K.O., Green P.G., and Levine J.D. Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. J. Neurosci. 15 (1995) 8031-18031
5. Aley K.O., and Levine J.D. Multiple receptors involved in peripheral alpha2, mu and A1 antinociception, tolerance and withdrawal. J. Neurol. Sci. 17 (1997) 735-744
6. Andersson M., Usiello A., Borgkvist A., Pozzi L., Dominguez C., Fienberg A.A., Svenningsson P., Fredholm B.B., Borrelli E., Greengard P., and Fisone G. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 25 (2005) 8432-8438
7. Antoniou K., Papadopoulou-Daifoti Z., Hyphantis T., Papathanasiou G., Bekris E., Marselos M., Panlilio L., Muller C.E., Goldberg S.R., and Ferré S. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology 183 (2005) 154-162
8. Arolfo M.P., Yao L., Gordon A.S., Diamond I., and Janak P.H. Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. Alcohol Clin. Exp. Res. 28 (2004) 1308-1316
9. Bailey A., Ledent C., Kelly M., Hourani S.M., and Kitchen I. Changes in spinal delta and kappa opioid systems in mice deficient in the A2A receptor gene. J. Neurosci. 22 (2002) 9210-9220
10. Bailey A., Davis L., Lesscher H.M., Kelly M.D., Ledent C., Hourani S.M., and Kitchen I. Enhanced morphine withdrawal and mu-opioid receptor G-protein coupling in A2A adenosine receptor knockout mice. J. Neurochem. 88 (2003) 827-834
11. Bailey A., Weber D., Zimmer A., Zimmer A.M., Hourani S.M., and Kitchen I. Quantitative autoradiography of adenosine receptors and NBTI-sensitive adenosine transporters in the brains of mice deficient in the preproenkephalin gene. Brain Res. 1025 (2004) 1-9
12. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
13. Basheer R., Strecker R.E., Thakkar M.M., and McCarley R.W. Adenosine and sleep-wake regulation. Prog. Neurobiol. 73 (2004) 379-396
14. Bastia E., Varani K., Monopoli A., and Bertorelli R. Effects of A1 and A2A adenosine receptor ligands in mouse acute models of pain. Neurosci. Lett. 328 (2002) 241-244
15. Belfrage M., Sollevi A., Segerdahl M., Sjolund K.F., and Hansson P. Systemic adenosine infusion alleviates spontaneous and stimulus-evoked pain in patients with peripheral neuropathic pain. Anesth. Analg. 81 (1995) 713-717
16. Belfrage M., Segerdahl M., Arner S., and Sollevi A. The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth. Analg. 89 (1999) 136-142
17. Berrendero F., Castane A., Ledent C., Parmentier M., Maldonado R., and Valverde O. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur. J. Neurosci. 17 (2003) 315-324
18. Beuckmann C.T., Lazarus M., Gerashchenko D., Mizoguchi A., Nomura S., Mohri I., Uesugi A., Kaneko T., Mizuno N., Hayaishi O., and Urade Y. Cellular localization of lipocalin-type prostaglandin D synthase (beta-trace) in the central nervous system of the adult rat. J. Comp. Neurol. 428 (2000) 62-78
19. Blumer J.B., Cismowski M.J., Sato M., and Lanier S.M. AGS proteins: receptor-independent activators of G-protein signaling. Trends Pharmacol. Sci. 26 (2005) 470-476
20. Borghi V., Przewlocka B., Labuz D., Maj M., Ilona O., and Pavone F. Formalin-induced pain and mu-opioid receptor density in brain and spinal cord are modulated by A1 and A2a adenosine agonists in mice. Brain Res. 956 (2002) 339-348
21. Bossert J.M., Ghitza U.E., Lu L., Epstein D.H., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur. J. Pharmacol. 526 (2005) 36-50
22. Bowers M.S., McFarland K., Lake R.W., Peterson Y.K., Lapish C.C., Gregory M.L., Lanier S.M., and Kalivas P.W. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron 42 (2004) 269-281
23. Brooke R.E., Deuchars J., and Deuchars S.A. Input-specific modulation of neurotransmitter release in the lateral horn of the spinal cord via adenosine receptors. J. Neurosci. 24 (2004) 127-137
24. Carriba P., Ortiz O., Patkar K., Justinova Z., Stroik J., Themann A., Müller C., Woods A.S., Hope B.T., Ciruela F., Casadó V., Canela E.I., Lluis C., Goldberg S.R., Moratalla R., Franco R., and Ferré S. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32 (2007) 2249-2259
25. Chen J.F., Beilstein M., Xu Y.H., Turner T.J., Moratalla R., Standaert D.G., Aloyo V.J., Fink J.S., and Schwarzschild M.A. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97 (2000) 195-204
26. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., Beilstein M.A., Hackett E., Fink J.S., Low M.J., Ongini E., and Schwarzschild M.A. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1970-1975
27. Chen J.F., Moratalla R., Yu L., Martin A.B., Xu K., Bastia E., Hackett E., Alberti I., and Schwarzschild M.A. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 28 (2003) 1086-1095
28. Chern Y. Regulation of adenylyl cyclase in the central nervous system. Cell Signal. 12 (2000) 195-204
29. Choca J.I., Proudfit H.K., and Green R.D. Identification of A1 and A2 adenosine receptors in the rat spinal cord. J. Pharmacol. Exp. Ther. 242 (1987) 905-910
30. Ciruela F., Casado V., Rodrigues R.J., Lujan R., Burgueno J., Canals M., Borycz J., Rebola N., Goldberg S.R., Mallol J., Cortes A., Canela E.I., Lopez-Gimenez J.F., Milligan G., Lluis C., Cunha R.A., Ferré S., and Franco R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 26 (2006) 2080-2087
31. Comer S.D., and Carroll M.E. Oral caffeine pretreatment produced modest increases in smoked cocaine self-administration in rhesus monkeys. Psychopharmacology 126 (1996) 281-285
32. De Lander G.E., Mosberg H.I., and Porreca F. Involvement of adenosine in antinociception produced by spinal or supraspinal receptor-selective opioid agonists: dissociation from gastrointestinal effects in mice. J. Pharmacol. Exp. Ther. 263 (1992) 1097-1104
33. De Lander G.E., and Keil II G.J. Antinociception induced by intrathecal coadministration of selective adenosine receptor and selective opioid receptor agonists in mice. J. Pharmacol. Exp. Ther. 268 (1994) 943-951
34. De Vries L., Zheng B., Fischer T., Elenko E., and Farquhar M.G. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 235-271
35. De Vries T.J., and Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 26 (2005) 420-426
36. Di Chiara G., Tanda G., Bassareo V., Pontieri F., Acquas E., Fenu S., Cadoni C., and Carboni E. Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann. N.Y. Acad. Sci. 877 (1999) 461-485
37. Dickenson A.H., and Sullivan A.F. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurons. Neurosci. Lett. 83 (1987) 207-211
38. Dickenson A.H., Suzuki R., and Reeve A.J. Adenosine as a potential analgesic target in inflammatory and neuropathic pains. CNS Drugs 13 (2000) 77-85
39. Doak G.J., and Sawynok J. Complex role of peripheral adenosine in the genesis of the response to subcutaneous formalin in the rat. Eur. J. Pharmacol. 281 (1995) 311-318
40. Dowd E., McQueen D.S., Chessell I.P., and Humphrey P.P. Adenosine A1 receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic rat knee joint. Br. J. Pharmacol. 125 (1998) 1267-1271
41. Ferré S., Fuxe K., von Euler G., Johansson B., and Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 51 (1992) 501-512
42. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 133 (1997) 107-120
43. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
44. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Muller C.E., Stromberg I., Ogren S.O., and Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7 (2001) 235-241
45. Ferré S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueno J., Gutierrez M.A., Casado V., Fuxe K., Goldberg S.R., Lluis C., Franco R., and Ciruela F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11940-11945
46. Ferré S., Borycz J., Goldberg S.R., Hope B.T., Morales M., Lluis C., Franco R., Ciruela F., and Cunha R. Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J. Integr. Neurosci. 4 (2005) 445-464
47. Ferré S., Agnati L.F., Ciruela F., Lluis C., Woods A.S., Fuxe K., and Franco R. Neurotransmitter receptor heteromers and their integrative role in "local modules". The striatal spine module. Brain Res. Rev. 55 (2007) 55-67
48. Filip M., Frankowska M., Zaniewska M., Przegalinski E., Muller C.E., Agnati L., Franco R., Roberts D.C., and Fuxe K. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 1077 (2006) 67-80
49. Fredholm B.B., and Vernet L. Morphine increases depolarization induced purine release from rat cortical slices. Acta Physiol. Scan. 104 (1978) 502-504
50. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
51. Fredholm B.B., Irenius E., Kull B., and Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61 (2001) 443-448
52. 2A receptors in the ventrolateral preoptic nucleus. Neuroscience 134 (2005) 1377-1390
53. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 81 (2005) 263-284
54. Gasior M., Jaszyna M., Peters J., and Goldberg S.R. Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J. Pharmacol. Exp. Ther. 295 (2000) 1101-1111
55. Gauvin D.V., Criado J.R., Moore K.R., and Holloway F.A. Potentiation of cocaine's discriminative effects by caffeine: a time-effect analysis. Pharmacol. Biochem. Behav. 36 (1990) 195-197
56. Gerfen C.R. Basal Ganglia. In: Paxinos G. (Ed). The Rat Nervous System (2004), Elsevier Academic Press, Amsterdam 445-508
57. Godfrey L., Yan L., Clarke G.D., Ledent C., Kitchen I., and Hourani S.M.O. Modulation of paracetamol antinoiception by caffeine and by selective adenosine A2 receptor antagonists in mice. Eur. J. Pharmacol. 531 (2006) 80-86
58. Green T.A., and Schenk S. Dopaminergic mechanism for caffeine-produced cocaine seeking in rats. Neuropsychopharmacology 26 (2002) 422-430
59. Grondin R., Bedard P.J., Hadj Tahar A., Gregoire L., Mori A., and Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
60. Hauber W., Neuscheler P., Nagel J., and Muller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur. J. Neurosci. 14 (2001) 1287-1293
61. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
62. 2. FASEB J. 5 (1991) 2575-2581
63. 2A receptor are involved in the homeostatic regulation of nrem sleep. Arch. Ital. Biol. 142 (2004) 533-539
64. 2 in activating histaminergic neurotransmission. Drug News Perspect. 17 (2004) 105-109
65. Hayaishi, O., Urade, Y. Prostaglandins and sleep/wake regulation. The Neurochemistry of Sleep and Wakefulness, in press.
66. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Coughenour L.L., and Downs D.A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 98 (1989) 31-37
67. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
68. Hong Z.Y., Huang Z.L., Qu W.M., Eguchi N., Urade Y., and Hayaishi O. An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J. Neurochem. 92 (2005) 1542-1549
69. Horger B.A., Wellman P.J., Morien A., Davies B.T., and Schenk S. Caffeine exposure sensitizes rats to the reinforcing effects of cocaine. Neuroreport 2 (1991) 53-56
70. Horvitz J.C. Dopamine gating of glutamatergic sensorimotor and incentive motivational input signals to the striatum. Behav. Brain Res. 137 (2002) 65-74
71. 1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. 8 (2005) 858-859
72. Huang Z.L., Urade Y., and Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr. Opin. Pharmacol. 7 (2007) 33-38
73. Hummel M., and Unterwald E.M. Intra-accumbens pertussis toxin sensitizes rats to the locomotor activating effects of a single cocaine challenge. Brain Res 965 (2003) 100-107
74. Hussey M., Clarke G.D., Ledent C., Hourani S.M.O., and Kitchen I. Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice. Pain 129 (2007) 287-294
75. Inoué S. Biology of Sleep Substances (1989), CRC Press, Boca Raton, FL
76. Ishiwata K., Mishina M., Kimura Y., Oda K., Sasaki T., and Ishii K. First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 55 (2005) 133-136
77. Jegou S., Yacoubi M.E., Mounien L., Ledent C., Parmentier M., Costentin J., Vaugeois J.M., and Vaudry H. Adenosine A2A receptor gene disruption provokes marked changes in melanocortin content and pro-opiomelanocortin gene expression. J. Neuroendocrinol. 15 (2003) 1171-1177
78. Johansson B., Georgiev V., and Fredholm B.B. Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors. Neuroscience 80 (1997) 1187-1207
79. Johansson B., Halldner L., Dunwiddie T.V., Masino S.A., Poelchen W., Gimenez-Llort L., Escorihuela R.M., Fernandez-Teruel A., Wiesenfeld-Hallin Z., Xu X.J., Hardemark A., Betsholtz C., Herlenius E., and Fredholm B.B. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9407-9412
80. Justinova Z., Ferré S., Segal P.N., Antoniou K., Solinas M., Pappas L.A., Highkin J.L., Hockemeyer J., Munzar P., and Goldberg S.R. Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J. Pharmacol. Exp. Ther. 307 (2003) 977-986
81. Kaelin-Lang A., Lauterburg T., and Burgunder J.M. Expression of adenosine A2a receptor gene in rat dorsal root and autonomic ganglia. Neurosci. Lett. 246 (1998) 21-24
82. Kalivas P.W., and Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162 (2005) 1403-1413
83. Kanda T., Shiozaki S., Shimada J., Suzuki F., and Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256 (1994) 263-268
84. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., and Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43 (1998) 507-513
85. Kaplan G.B., and Leite-Morris K.A. Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res. 763 (1997) 215-220
86. Kaplan G.B., Leite-Morris K.A., and Sears M.T. Alterations of adenosine A1 receptors in morphine dependence. Brain Res. 657 (1994) 347-350
87. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pezzola A., Reggio R., Muller C.E., Fuxe K., Goldberg S.R., Popoli P., and Ferré S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 (2003) 1281-1291
88. Karlsten R., Gordh T., and Post C. Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice. Pharmacol. Toxicol. 70 (1992) 434-438
89. Kelley A.E. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 30 (2004) 161-179
90. Kelly M., Bailey A., Ledent C., Kitchen I., and Hourani S. Characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A receptor knockout mice. Eur. J. Pharmacol. 504 (2004) 55-59
91. Kirkup A.J., Eastwood C., Grundy D., Chessell I.P., and Humphrey P.P.A. Characterisaion of adenosine receptors evoking excitation of mesenteric afferents in the rat. Br. J. Pharmacol. 125 (1998) 1352-1360
92. Knapp C.M., Foye M.M., Cottam N., Ciraulo D.A., and Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 68 (2001) 797-803
93. Kubota K. Kuniomi Ishimori and the first discovery of sleep-inducing substances in the brain. Neurosci. Res. 6 (1989) 497-518
94. Kuzmin A., Johansson B., Zvartau E.E., and Fredholm B.B. Caffeine, acting on adenosine A(1) receptors, prevents the extinction of cocaine-seeking behavior in mice. J. Pharmacol. Exp. Ther. 290 (1999) 535-542
95. 2A agonists in development for the treatment of inflammation. Exp. Opin. Invest. Drugs 14 (2005) 797-806
96. Ledent C., Vaugeois J., Schiffman S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J., Costentin J., Heath J.K., Vassart G., and Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388 (1997) 674-678
97. Lee Y.W., and Yaksh T.L. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J. Pharmacol. Exp. Ther. 277 (1996) 1642-1648
98. Lillrank S.M., Lipska B.K., Weinberger D.R., Fredholm B.B., Fuxe K., and Ferré S. Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem. Int. 34 (1999) 235-244
99. Liu X.J., White T.D., and Sawynok J. Potentiation of formalin-evoked adenosine release by an adenosine kinase inhibitor and an adenosine deaminase inhibitor in the rat hind paw: a microdialysis study. Eur. J. Pharmacol. 408 (2000) 143-152
100. Liu X.J., White T.D., and Sawynok J. Involvement of primary sensory afferents, postganglionic sympathetic nerves and mast cells in the formalin-evoked peripheral release of adenosine. Eur. J. Pharmacol. 429 (2001) 147-155
101. Liu X.J., and Salter M.W. Purines and pain mechanisms: recent developments. Curr. Opin. Investig. Drugs 6 (2005) 65-75
102. Logan L., Carney J.M., Holloway F.A., and Seale T.W. Effects of caffeine, cocaine and their combination on fixed-interval behavior in rats. Pharmacol. Biochem. Behav. 33 (1989) 99-104
103. Lopes L.V., Halldner L., Rebola N., Johansson B., Ledent C., Chen J.F., Fredholm B.B., and Cunha R.A. Binding of the prototypical adenosine A2A receptor agonist CGS 21680 to the cerebral cortex of adenosine A1 and A2A receptor knockout mice. Br. J. Pharmacol. 141 (2004) 1006-1014
104. Lu X.Y., Ghasemzadeh M.B., and Kalivas P.W. Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82 (1998) 767-780
105. Millan M.J. The induction of pain: an integrative review. Prog. Neurobiol. 57 (1999) 1-164
106. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
107. Misra A.L., Vadlamani N.L., and Pontani R.B. Effect of caffeine on cocaine locomotor stimulant activity in rats. Pharmacol. Biochem. Behav. 24 (1986) 761-764
108. Mizoguchi A., Eguchi N., Kimura K., Kiyohara Y., Qu W.M., Huang Z.L., Mochizuki T., Lazarus M., Kobayashi T., Kaneko T., Narumiya S., Urade Y., and Hayaishi O. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11674-11679
109. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
110. Montegazza P., Tammiso R., Zambotti F., Zecca L., and Zonta S. Purine involvement in morphine antinociception. Br. J. Pharmacol. 83 (1984) 883-888
111. Morairty S., Rainnie D., McCarley R., and Greene R. Disinhibition of ventrolateralpreoptic area sleep-active neurons by adenosine: a new mechanism for sleep promotion. Neuroscience 123 (2004) 451-457
112. Munzar P., Justinova Z., Kutkat S.W., Ferré S., and Goldberg S.R. Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology 161 (2002) 348-355
113. Nestler E.J., Terwilliger R.Z., Walker J.R., Sevarino K.A., and Duman R.S. Chronic cocaine treatment decreases levels of the G protein subunits Gi alpha and Go alpha in discrete regions of rat brain. J. Neurochem. 55 (1990) 1079-1082
114. Newman H.M., Stevens R.T., and Apkarian A.V. Direct spinal projections to limbic and striatal areas: anterograde transport studies from the upper cervical spinal cord and the cervical enlargement in squirrel monkey and rat. J. Comp. Neurol. 365 (1996) 640-658
115. Parent A., and Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20 (1995) 91-127
116. Pechlivanova D.M., and Georgiev V.P. Interaction of angiotensin II and adenosine A1 and A2A receptor ligands on the writhing test in mice. Pharmacol. Biochem. Behav. 72 (2002) 23-38
117. Phillis J.W.C., and Jiang Z.G.W. The effect of morphine on purine and acetylcholine release from rat cerebral cortex: evidence for a purinergic component in morphine's action. Pharmacol. Biochem. Behav. 13 (1980) 421-427
118. Poleszak E., and Malec D. Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity. Pol. J. Pharmacol. 54 (2002) 359-366
119. Pollack A.E., and Fink J.S. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68 (1995) 721-728
120. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 12304-12308
121. Poon A., and Sawynok J. Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat. Pain 74 (1998) 235-245
122. Popoli, P., Pezzola, A., de Carolis, A.S., 1994. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur. J. Pharmacol. 12, 257, 21-25.
123. Porkka-Heiskanen T., Strecker R.E., and McCarley R.W. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 99 (2000) 507-517
124. 2 involved in regulation of physiological sleep. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 17949-17954
125. Quarta D., Ferré S., Solinas M., You Z.B., Hockemeyer J., Popoli P., and Goldberg S.R. Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J. Neurochem. 88 (2004) 1151-1158
126. Quarta D., Borycz J., Solinas M., Patkar K., Hockemeyer J., Ciruela F., Lluis C., Franco R., Woods A.S., Goldberg S.R., and Ferré S. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-d-aspartate receptor stimulation. J. Neurochem. 91 (2004) 873-880
127. Quiroz C., Gomes C., Pak A.C., Ribeiro J.A., Goldberg S.R., Hope B.T., and Ferré S. Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. J. Neurosci. 26 (2006) 10808-108012
128. Rahman Z., Schwarz J., Gold S.J., Zachariou V., Wein M.N., Choi K.H., Kovoor A., Chen C.K., DiLeone R.J., Schwarz S.C., Selley D.E., Sim-Selley L.J., Barrot M., Luedtke R.R., Self D., Neve R.L., Lester H.A., Simon M.I., and Nestler E.J. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38 (2003) 941-952
129. Reeve A.J., and Dickenson A.H. Electrophysiological study on spinal antinociceptive interactions between adenosine and morphine in the dorsal horn of the rat. Neurosci. Lett. 194 (1995) 81-84
130. Rimondini R., Ferré S., Ogren S.O., and Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17 (1997) 82-91
131. Rinne J.O. Nigral degeneration in Parkinson's disease. Mov. Disord. 1 8 Suppl. (1993) S31-S35
132. Robertson G.S., and Jian M. D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience 64 (1995) 1019-1034
133. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
134. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., and Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 401 (1998) 163-186
135. Rosin D.L., Hettinger B.D., Lee A., and Linden J. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61 (2003) S12-S18
136. Ross E.M., and Wilkie T.M. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu. Rev. Biochem. 69 (2000) 795-827
137. Saper C.B., Chou T.C., and Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 24 (2001) 726-731
138. Saper C.B., Scammell T.E., and Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
139. 2 in rats. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5980-5984
140. 2A receptor in sleep promotion. Eur. J. Pharmacol. 351 (1998) 155-162
141. 2A receptor agonist. Eur. J. Neurosci. 11 (1999) 1587-1597
142. Sawynok J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 347 (1998) 1-11
143. Sawynok J., and Liu X.J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69 (2003) 313-340
144. 2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107 (2001) 653-663
145. 2. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7754-7759
146. Schenk S., Worley C.M., McNamara C., and Valadez A. Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology 126 (1996) 17-23
147. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
148. Segerdahl M. Antinociceptive effects of adenosine infusion in man. Assessments in experimentally induced pain and in surgery. Acta Anaesthesiol. Scand. 41 (1997) 90-190
149. Segerdahl M., Ekblom A., Sandelin K., Wickman M., and Sollevi A. Peroperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesth. Analg. 80 (1995) 1145-1149
150. Segerdahl M., and Sollevi A. Adenosine and pain relief: a clinical overview. Drug Dev. Res. 45 (1998) 151-158
151. Self D.W., Terwilliger R.Z., Nestler E.J., and Stein L. Inactivation of Gi and G(o) proteins in nucleus accumbens reduces both cocaine and heroin reinforcement. J. Neurosci. 14 (1994) 6239-6247
152. Self D.W., Barnhart W.J., Lehman D.A., and Nestler E.J. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271 (1996) 1586-1589
153. Sherin J.E., Shiromani P.J., McCarley R.W., and Saper C.B. Activation of ventrolateral preoptic neurons during sleep. Science 271 (1996) 216-219
154. Shimazoe T., Yoshimatsu A., Kawashimo A., and Watanabe S. Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization. Eur. J. Pharmacol. 388 (2000) 249-254
155. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., and Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147 (1999) 90-95
156. Solinas M., Ferré S., You Z.B., Karcz-Kubicha M., Popoli P., and Goldberg S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neurosci. 22 (2002) 6321-6324
157. Solinas M., Ferré S., Antoniou K., Quarta D., Justinova Z., Hockemeyer J., Pappas L.A., Segal P.N., Wertheim C., Muller C.E., and Goldberg S.R. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology 179 (2005) 576-586
158. Soria G., Castane A., Berrendero F., Ledent C., Parmentier M., Maldonado R., and Valverde O. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur. J. Neurosci. 20 (2004) 2203-2213
159. Soria G., Castane A., Ledent C., Parmentier M., Maldonado R., and Valverde O. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31 (2005) 978-987
160. Stone T.W. The effects of morphine and methionine enkephalin on the release of purines from cerebral cortex slices of rats and mice. Br. J. Pharmacol. 74 (1981) 171-176
161. Striplin C.D., and Kalivas P.W. Robustness of G protein changes in cocaine sensitization shown with immunoblotting. Synapse 14 (1993) 10-15
162. Suh H.W., Song D.K., and Kim Y.H. Differential effects of adenosine receptor antagonists injected intrathecally on antinociception induced by morphine and beta-endorphin administered intracerebroventricularly in the mouse. Neuropeptides 31 (1997) 339-444
163. Svenningsson P., Le Moine C., Kull B., Sunahara R., Bloch B., and Fredholm B.B. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80 (1997) 1171-1185
164. Svenningsson P., Hall H., Sedvall G., and Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 27 (1997) 322-335
165. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59 (1999) 355-396
166. Sweeney M.I., White T.D., Jhamandas K.H., and Sawynok J. Morphine releases endogenous adenosine from the spinal cord in vivo. Eur. J. Pharmacol. 141 (1987) 169-170
167. + release purines from capsaicin-sensitive primary afferent nerve terminals in the spinal cord. J. Pharmacol. Exp. Ther. 248 (1989) 447-454
168. Taiwo Y.O., and Levine J.D. Direct cutaneous hyperalgesia induced by adenosine. Neurosci. 38 (1990) 757-762
169. Tanganelli S., Sandager Nielsen K., Ferraro L., Antonelli T., Kehr J., Franco R., Ferré S., Agnati L.F., Fuxe K., and Scheel-Kruger J. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat. Disord. 10 (2004) 273-280
170. Terwilliger R.Z., Beitner-Johnson D., Sevarino K.A., Crain S.M., and Nestler E.J. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548 (1991) 100-110
171. Thomas E.A., Danielson P.E., and Sutcliffe J.G. RGS9: a regulator of G-protein signalling with specific expression in rat and mouse striatum. J. Neurosci. Res. 52 (1998) 118-124
172. 2A receptor-deficient mice. Neurology 61 (2003) S94-S96
173. Ward R.P., and Dorsa D.M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Neuroscience 89 (1999) 927-938
174. Wardas J., Konieczny J., and Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41 (2001) 160-171
175. Weerts E.M., and Griffiths R.R. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology 168 (2003) 155-163
176. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5 (2004) 483-494
177. Wolf M.E. Addiction: making the connection between behavioral changes and neuronal plasticity in specific pathways. Mol. Interv. 2 (2002) 146-157
178. Worley C.M., Valadez A., and Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol. Biochem. Behav. 48 (1994) 217-421
179. Wu W.P., Hao J.X., Halldner L., Lovdahl C., DeLander G.E., Wiesenfeld-Hallin Z., Fredholm B.B., and Xu X.J. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 113 (2005) 395-404
180. Yao L., Arolfo M.P., Dohrman D.P., Jiang Z., Fan P., Fuchs S., Janak P.H., Gordon A.S., and Diamond I. betagamma Dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell 109 (2002) 733-743
181. Yao L., Fan P., Jiang Z., Mailliard W.S., Gordon A.S., and Diamond I. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 14379-14384
182. Yao L., McFarland K., Fan P., Jiang Z., Inoue Y., and Diamond I. Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8746-8751
183. Yao L., McFarland K., Fan P., Jiang Z., Ueda T., and Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7877-7882
184. Zarrindast M.R., and Nikfar S. Different influences of adenosine receptor agonists and antagonists on morphine antinociception in mice. Gen. Pharmacol. 25 (1994) 139-142
185. Zhang K., Tarazi F.I., Campbell A., and Baldessarini R.J. GABA(B) receptors: altered coupling to G-proteins in rats sensitized to amphetamine. Neuroscience 101 (2000) 5-10